Evaluation of ABX-001 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Beyond Standard of Care

The primary objective of this study is to evaluate the efficacy and safety of a new **immunotherapy**, ABX-001, both as a monotherapy and in combination with the marketed drug pembrolizumab, in patients with **advanced solid tumors** who have exhausted standard treatment options. This investigation is clinically relevant as it aims to provide alternative therapeutic strategies for patients with limited treatment choices, potentially improving outcomes in a population with high unmet medical needs.

The clinical trial involves participants diagnosed with **advanced solid tumors** who have exhausted standard care options. The study population includes both male and female subjects, with an age range spanning from young adults to older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on their medical condition, and no specific lifestyle considerations such as diet or physical activity are highlighted. Key inclusion or exclusion criteria have not been disclosed by the sponsor.

The clinical trial is designed to evaluate the efficacy and safety of a new **immunotherapy**, ABX-001, both as a monotherapy and in combination with pembrolizumab, for patients with **advanced solid tumors** who have exhausted standard treatment options. This is a Phase 1 trial, characterized by a randomized, double-blind, and controlled design, ensuring that neither the participants nor the researchers know who is receiving the experimental treatment or the control, thereby minimizing bias. The trial is expected to commence recruitment on June 30, 2025, and is projected to conclude by March 22, 2027, encompassing a total duration of approximately 21 months.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This visit will involve a comprehensive review of the participant's medical history, physical examination, and necessary laboratory tests to confirm the presence of advanced solid tumors and ensure the absence of exclusion criteria. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are scheduled to monitor the participant's response to the treatment, assess any adverse effects, and ensure adherence to the study protocol. The frequency and specific assessments conducted during these visits will be determined by the study protocol.

The end-of-study visit marks the conclusion of the participant's involvement in the trial. During this visit, final evaluations will be conducted to gather data on the long-term effects of the treatment and to ensure the participant's well-being post-trial. The expected length of participant involvement will vary depending on individual response to treatment and the occurrence of any adverse events. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed necessary by the investigator to protect the participant's health. The trial's design and procedures are meticulously structured to ensure the collection of reliable data while prioritizing participant safety and ethical standards.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is available from the provided data. Consequently, a detailed description of the experimental treatment cannot be provided.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these treatments cannot be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is not provided in the data. As such, these details cannot be elaborated upon in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating its primary focus on safety and dosage, with preliminary efficacy assessments. The trial is scheduled to commence recruitment on June 30, 2025, and is estimated to conclude by March 22, 2027. Although specific efficacy endpoints are not detailed, typical Phase 1 trials may involve the collection of data related to **biomarkers** or initial symptom improvement to inform future studies. The methodology for measuring and analyzing efficacy parameters will likely involve standardized and validated tools appropriate for the condition under investigation. Data collection will be systematically scheduled throughout the trial duration to ensure comprehensive assessment of the investigational product's potential efficacy.